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Abstract
Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, liver failure, and hepatocellular car-
cinoma. Although the combination therapy employing pegylated interferon (IFN)-a and ribavirin is effective,
this treatment is effective in only approximately 50% patients with genotype 1 HCV infection. IFN-c is a potent
anti-HCV agent that exhibits its antiviral action through a receptor distinct from that for IFN-a. Therefore, IFN-c
application might provide an alternative approach to IFN-a-based therapies. However, recombinant IFN-c
protein exhibits a poor pharmacokinetic property, that is, a very short half-life. It is our hypothesis that sustained
IFN-c serum concentrations produced by gene transfer could effectively eliminate HCV in vivo. We examined the
in vivo antiviral activity in human hepatocyte chimeric mice infected with genotype 1b HCV at high HCV RNA
titers (105–107 copies/ml). The human IFN-c-expressing plasmid vector pCpG-huIFNc exhibited prolonged
transgene expression in mice compared with the plasmid vector pCMV-huIFNc. Moreover, the gene transfer of
pCpG-huIFNc eliminated HCV from the liver of the chimeric mice for a sustained period. On the contrary,
administration of pCMV-huIFNc could not eliminate HCV. In conclusion, we found that a single pCpG-huIFNc
injection resulted in long-term elimination of HCV RNA in chimeric mice, providing, for the first time, direct
evidence that chronic infection with high titer HCV in vivo can be treated by sustained IFN-c treatment.
Introduction
Chronic hepatitis C virus (HCV) infection is a leadingcause of cirrhosis, liver failure, and hepatocellular carci-
noma (Niederau et al., 1998). At present, the standard treat-
ment for chronic HCV patients is a combination of pegylated
interferon (IFN)-a and ribavirin (Manns et al., 2001; Fried et al.,
2002). However, approximately only 50% of patients with
genotype 1 HCV infection and a high viral load showed a
sustained viral response, which is associated with resistance
to IFN-a (Hofmann et al., 2005; Chayama and Hayes, 2011).
More recently, telaprevir, an HCV protease inhibitor, ad-
ministered in combination with pegylated IFN and ribavirin
has led to high rates of sustained virologic response. How-
ever, approximately 30% of patients with HCV genotype 1
infection did not respond to the combination treatment
(Sherman et al., 2011). Therefore, extensive efforts have been
made to develop novel anti-HCV therapies that work via
different mechanisms from that of IFN-a.
In vitro cell culture studies using HCV subgenomic re-
plicon systems have demonstrated that IFN-c (type II IFN) is
a potent cytokine with anti-HCV activities (Cheney et al.,
2002; Frese et al., 2002; Windisch et al., 2005). The IFN-c an-
tiviral effects were stronger and more sustained than those of
type I IFNs, such as IFN-a and IFN-b (Cheney et al., 2002).
Moreover, IFN-c biological actions are mediated by a unique
signal transduction pathway through cell surface receptors
that are distinct from those of type I IFNs. Therefore, IFN-c
application could be an alternative therapeutic strategy for
chronic HCV infection to overcome the drawbacks associ-
ated with present IFN-a-based therapies.
On the basis of the findings regarding IFN-c anti-HCV
activities, the therapeutic efficacy of IFN-c was evaluated in
chronic HCV patients. However, IFN-c had little or no
therapeutic effect in chronic HCV patients (Saez-Royuela
et al., 1991; Soza et al., 2005). Although IFN-c was repeatedly
administered at high doses in these studies, the very short
in vivo half-life of IFN-c might have hampered its therapeutic
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potential. IFN-c disappears rapidly from the systemic circu-
lation because it has a half-life ranging from several minutes
to several hours after intravenous or intramuscular admin-
istration in humans, probably because of its rapid urinary
excretion and degradation (Foon et al., 1985; Wills, 1990).
Among the various strategies for manipulating IFN-c
pharmacokinetics, in vivo IFN-c gene transfer could be a
useful method if prolonged transgene expression can be
achieved. Shin et al. (2005) have investigated whether liver-
directed IFN-c gene transfer using viral vectors was effective
in reducing serum HCV RNA titers in primates. They did not
observe a significant decrease of circulating viral RNA after
multiple IFN-c gene deliveries, and the modest variations in
HCV RNA level observed were within the normal fluctua-
tions in the viral load. The IFN-c mRNA level in the liver
after IFN-c gene transfer was relatively low and rapidly
declined with time, probably because of induction of im-
mune responses. We speculated that a limited level and short
duration of IFN-c expression caused by immune responses
might be the reason for the poor anti-HCV effect of IFN-c
and that the utilization of a nonviral vector would be effec-
tive in overcoming this concern. In our series of studies, we
demonstrated that the mouse IFN-c-expressing plasmid
pCpG-muIFNc produced high serum IFN-c levels for > 80
days after a single administration and produced a significant
therapeutic effect in NC/Nga mice, a model for human
atopic dermatitis (Hattori et al., 2010). On the basis of these
findings, we hypothesized that sustained supplementation of
human IFN-c expressed from the pCpG vector could result in
an in vivo antiviral effect on genotype 1 HCV.
Repopulation of the liver with human hepatocytes can be
induced using immunodeficient urokinase-type plasminogen
activator (uPA) mice, and the human hepatocytes in the mice
can be used in HCV infection experiments (Mercer et al.,
2001). We and other group previously demonstrated that
administration of IFN-a and pegylated IFN-a can reduce
HCV RNA level in the serum in this model (Inoue et al., 2007;
Hiraga et al., 2009; Abe et al., 2011). Here, we investigated the
effects of IFN-c gene transfer on HCV infection using HCV-
infected human hepatocyte chimeric mice.
Materials and Methods
Plasmid DNA
The human IFN-c-expressing plasmid vectors pCpG-
huIFNc and pCMV-huIFNc (described as phCMVenh/
prom-huIFNc previously) were constructed as described
previously (Ando et al., 2012). pCpG-gLuc-encoding Gaussia
luciferase (GLuc) was constructed by inserting the GLuc
cDNA fragment from the pGLuc-Basic vector (New England
Biolab, Madison, WI) into pCpG-mcs (InvivoGen, San Diego,
CA). The enhanced green fluorescent protein (EGFP)-
expressing plasmid vector pEGFP-N1 was purchased from
BD Biosciences Clontech (Palo Alto, CA).
Animal treatment
Generation of the immunodeficient uPA+/+/SCID+/+ mice
and transplantation of human hepatocytes were performed as
described previously (PhoenixBio Co., Ltd., Higashihiroshima,
Japan) (Tateno et al., 2004). All mice received transplants with
frozen human hepatocytes obtained from the same donor. All
animal protocols were carried out in accordance with the
guidelines of the local committee for animal experiments (Hir-
oshima University and Kyoto University). Infection, extraction
of serum samples, and euthanization of mice were performed
under ether anesthesia. Mouse serum concentrations of human
serum albumin (HSA), correlated with the repopulation index
(Tateno et al., 2004), were measured using the Human Albumin
ELISA Quantitation Kit (Bethyl Laboratories Inc., Montgomery,
TX). The chimeric mice with a high replacement rate with hu-
man hepatocytes were used in the present study. Eight weeks
after hepatocyte transplantation, mice were received an intra-
venous injection of 105 copies of HCV.
Human serum samples containing a high titer of genotype
1b HCV were obtained from two chronic hepatitis patients
(patient-A and patient-B) who had provided written in-
formed consent for their study participation. The study
protocol conformed to the ethics guidelines of the 1975 De-
claration of Helsinki and was approved by the review
committee of Hiroshima University.
In vivo IFN-c gene transfer in mice and HCV-infected
chimeric mice
Gene transfer to mouse liver was performed by the hy-
drodynamic injection method (Liu et al., 1999), which allows
very high transgene expression, especially in the liver. In
brief, ICR mice received a rapid injection of 0.11 lg naked
plasmid DNA dissolved in 0.08 ml saline/g body weight into
the tail vein within 5 sec. CB17/Icr-Prkdscid/CrlCrlj mice
received a rapid injection of 0.22 lg naked plasmid DNA
dissolved in 0.1 ml saline/g body weight into the tail vein
within 5 sec. Chimeric mice received 250 lg naked plasmid
DNA dissolved in 0.1 ml saline/g body weight into the tail
vein within 5 sec. Transfection efficiency in each chimeric
mouse was estimated by measuring the serum level of se-
cretory transgene products, that is, IFN-c and GLuc, because
IFN-c and GLuc were not detected in untreated chimeric
mouse serum and because serum concentration of secretory
proteins reflects the transgene expression level in the liver.
Measurement of serum concentrations of IFN-c,
GLuc, and alanine aminotransferase
Mouse sera were collected at indicated times after gene
transfer. Human IFN-c concentrations were determined us-
ing a human IFN-c ELISA kit (Ready-Set-Go! human IFN-c
ELISA; eBioscience, San Diego, CA). To measure serum
GLuc activities, serum was mixed with sea pansy luciferase
assay buffer (PiccageneDual; Toyo Ink, Tokyo, Japan), and
the chemiluminescence was measured in a luminometer.
Serum alanine aminotransferase (ALT) level was measured
by quantification kit (Transaminase CII test Wako; Wako
Pure Chemical, Osaka, Japan).
RNA extraction and amplification
RNA was extracted from serum and liver samples by Sepa
Gene RV-R (Sankojunyaku, Tokyo, Japan) and reverse tran-
scribed using a random primer (Takara Bio Inc., Shiga, Japan)
and M-MLV reverse transcriptase (ReverTra Ace; Toyobo
Co., Osaka, Japan). Nested polymerase chain reaction (PCR)
and quantitation of HCV by Light Cycler (Roche Diagnostic,
Tokyo, Japan) were performed as previously reported
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(Tateno et al., 2004; Kimura et al., 2008). The lower detection
limits were 102 copies/ml for nested PCR and 103 copies/ml
for real-time PCR.
Fluorescence analysis and histopathological analysis
of mouse liver
Mouse livers were excised 1 day after gene transfer with
pEGFP-N1, placed in Tissue-Tek OCT embedding compound
(Sakura Finetechnical Co., Ltd., Tokyo, Japan), and frozen in
liquid nitrogen. Frozen liver sections (8lm thick) were ob-
tained using a cryostat ( Jung CM 3000; Leica Microsystems
AG, Wetzlar, Germany). The sections were stained with
HSA-specific antibody to visualize human hepatocytes. Liver
sections were fixed with 4% paraformaldehyde in phosphate-
buffered saline (PBS). After blocking with 20% fetal bovine
serum in PBS, the liver sections were incubated with poly-
clonal goat antibody against HSA (1:100 dilution). After
washing, Alexa Fluor 568 antigoat secondary antibody (1:500
dilution; Molecular Probes, Invitrogen, Carlsbad, CA) was
added, and the stained sections were observed using a con-
focal laser microscope (A1R MP; Nikon Instruments, Tokyo,
Japan). Liver samples obtained from pCpG-huIFNc-injected
mice were examined either by hematoxylin–eosin staining or
by immunohistochemical staining with anti-HSA antibody as
previously described (Hiraga et al., 2007).
Statistical analysis
Differences were evaluated by the Student’s t-test, and
p < 0.05 was considered statistically significant. The phar-
macokinetic parameters, area under the serum concentra-
tion–time curve (AUC), and mean residence time were
calculated for each animal by integration to the endpoint of
the experiment (Yamaoka et al., 1978).
Results
IFN-c expressed by pCpG-huIFNc shows antiviral
activity in HCV subgenomic replicon cells
In vitro IFN-c anti-HCV activity was evaluated using Luc-
Neo#2 cells. Supplementary Fig. S1A (Supplementary Data
are available online at www.liebertpub.com/humc) shows
the effect of recombinant IFN-c protein at different concen-
trations for 1 or 3 days on luciferase activity in LucNeo#2
cells. A dose- and time-dependent inhibitory effect was ob-
served. On the basis of these results, the antiviral activity of
IFN-c expressed after transfection with pCpG-huIFNc was
examined. A significant inhibitory effect was observed after
transfection, and a higher inhibition was observed at 3 days
(Supplementary Fig. S1B). IFN-c levels in the culture me-
dium were 2.9· 105 and 3.3· 106 pg/ml, corresponding to
approximately 700 and 7,800 IU/ml 1 and 3 days after
transfection, respectively (Supplementary Fig. S1C). IFN-c
was not detected in the culture supernatant from non-
transfected cells.
Hydrodynamic pCpG-huIFNc and pCMV-huIFNc
injection results in sustained and transient transgene
expression of human IFN-c, respectively
In our previous studies, we demonstrated sustained ex-
pression of murine IFN-c from pCpG-muIFNc, a CpG-depleted
plasmid vector, in mice after hydrodynamic injection, while
transient expression of murine IFN-c was observed after hy-
drodynamic injection of pCMV-muIFNc, a conventional CpG-
replete vector (Hattori et al., 2010). To confirm prolonged and
transient transgene expression of human IFN-c from the same
types of plasmid vectors, serum IFN-c concentrations were
measured in ICR mice using the hydrodynamic-based method.
The serum human IFN-c concentration was very high in the
initial phase and was maintained for up to approximately 240
days after a single hydrodynamic injection (Fig. 1A), while
pCMV-huIFNc failed to show any sustained gene expression.
A similar prolonged profile of human IFN-c was observed in
immunodeficient mice for up to 10 days after gene transfer
with pCpG-huIFNc, while the transient profile of serum hu-
man IFN-c concentration was observed after pCMV-huIFNc
injection (Fig. 1B).
Hydrodynamic plasmid DNA injection results
in transgene expression in the livers of human
hepatocyte chimeric mice
To examine whether in vivo gene transfer in the chimeric
mice is possible, we conducted an experiment using plasmid
DNA encoding GFP to visualize transgene expression in
chimeric mouse livers with a high replacement index of
human hepatocytes. GFP expression was observed in human
hepatocytes, which was confirmed by HSA-specific immuno-
fluorescent staining (Fig. 1C–E). It was found that approxi-
mately 1–2% of human hepatocytes were positive for GFP
(Supplementary Fig. S2).
A limited antiviral effect can be obtained in chimeric
mice infected with genotype 1b HCV after a single
injection of pCMV-huIFNc
To analyze the antiviral effect of IFN-c gene transfer
in vivo, chimeric mice with high HCV RNA titers (105–107
copies/ml) 9–12 weeks after HCV inoculation received gene
transfer of pCMV-huIFNc. We measured the HCV RNA titer
(upper panel), HSA concentration (middle panel), and IFN-c
concentration (lower panel) in serum after a single injection
of plasmid vector (Fig. 2A–D). In a mouse with serum HCV
titer of approximately 1· 106 copies/ml, the HCV RNA level
in serum decreased, but not to zero (Fig. 2A). HCV RNA was
also detected in the liver of this mouse by nested PCR (Fig.
2E). In other mice with high HCV titer (> 4· 106 copies/ml),
serum HCV titers fell slightly 1 week after gene transfer, but
the serum HCV titer rebounded later (Fig. 2B and C). In a
mouse that showed low serum IFN-c concentration after the
plasmid DNA administration, serum HCV RNA titer did not
decrease (Fig. 2D). These results imply that anti-HCV effect
observed in the present study is mediated by IFN-c.
A marked antiviral effect can be obtained in chimeric
mice infected with genotype 1b HCV after a single
injection of pCpG-huIFNc
To investigate whether more sustained supplementation
of IFN-c has a more effective antiviral effect in chimeric mice
infected with HCV, pCpG-huIFNc was administered to
HCV-infected human liver chimeric mice. As expected, more
sustained IFN-c expression was observed in each chimeric
mouse compared with that seen after the administration of
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pCMV-huIFN-c, although the absolute IFN-c levels varied to
a great extent. Immediately after pCpG-huIFNc injection
(day 3), HCV RNA levels in the pCpG-huIFNc-treated mice
fell dramatically in 5 of the 6 infected mice (Fig. 3A–E). In a
mouse that expressed very low human IFN-c levels (Fig. 3F),
serum HCV titers barely changed after gene transfer with
pCpG-huIFNc. Prolonged undetectable HCV serum levels
were observed for more than 7 weeks after gene transfer in
all of the surviving mice (n = 3) that expressed relatively high
human IFN-c levels. HCV was probably eliminated because
no HCV RNA was detected by nested PCR in the livers of the
three mice (Fig. 3G). pCpG #4 and pCpG #5 died at 14 and 16
weeks (2 and 4 weeks after IFN-c gene transfer, respectively)
(Fig. 3D and E), although a significant reduction in HCV
titers after IFN-c gene transfer was observed in both mice.
These results are summarized in Table 1.
The HCV RNA level in serum was not affected
in chimeric mice infected with genotype 1b HCV after
a single injection of GLuc-expressing plasmid DNA
Figure 4 shows the results after a hydrodynamic injection
of a control vector, pCpG-gLuc, that expresses a reporter
protein without any biological activity. Significant GLuc ex-
pression was observed in all HCV-infected chimeric mice after
in vivo gene transfer with pCpG-gLuc. Serum HCV RNA
levels did not change in the chimeric mice injected with the
control vector, which clearly indicates that the antiviral effect
observed in the pCpG-huIFNc-treated mice was caused by
IFN-c expression and not by hydrodynamic plasmid DNA
injection. After hydrodynamic plasmid DNA injection, the
HSA levels were hardly affected in any of the mice irrespec-
tive of the transgenes encoded by plasmid DNAs.
No apparent damage was observed in hepatocytes
of chimericmice after sustainedgeneexpressionof IFN-c
To evaluate hepatic toxicity induced by IFN-c, serum
ALT was measured before and after hydrodynamic injec-
tion of pCpG-huIFNc. As shown in Fig. 5, serum ALT ac-
tivity increased at 3–7 days after the administration, but it
returned to the level comparable to that before the admin-
istration later. As it was found that serum ALT increased at
3 days after the administration of pCpG-huIFNc, livers
were collected at 3 days after the plasmid DNA adminis-
tration. The liver sections were subjected to hematoxylin
eosin staining or to HSA-specific immunohistochemical
staining. No obvious damage was observed in the chimeric
mouse liver compared with the HCV-infected mouse left
untreated (Fig. 6A–D).
FIG. 1. Prolonged serum concentration of human IFN-c after hydrodynamic injection of pCpG-huIFNc and transgene expression
in human hepatocytes of the chimeric mice after hydrodynamic administration of plasmid DNA. (A and B) Plasmid DNA was
hydrodynamically injected into mice. (A) Four-week-old male ICR mice (normal mice) received an injection of 0.11lg of pCpG-
huIFNc (circle) or pCMV-huIFNc (triangle). (B) Six-week-old female CB17/Icr-Prkdcscid/CrlCrlj mice (immunodeficient mice)
received an injection of 0.22lg pCpG-huIFNc (circle) or pCMV-huIFNc (triangle). Each result represents the mean– SD of three
mice. (C–E) Human hepatocyte chimeric mice were injected with 250lg of plasmid DNA encoding EGFP. One day after gene
transfer, the liver was collected and the liver sections were stained with HSA-specific antibody. Typical images of sections
exhibiting red fluorescence (C; HSA), green fluorescence (D; EGFP), and green and red fluorescence (E; merged image) are shown.
Scale bar= 50lm. HSA, human serum albumin; IFN, interferon. Color images available online at www.liebertpub.com/humc
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To further evaluate a possible toxic effect on the liver in-
duced by sustained IFN-c expression in the liver, livers were
collected from the pCpG-huIFNc-treated chimeric mice or
pCpG-gLuc-treated chimeric mice at the end of the experi-
ments. As shown in Fig. 6E–H, no obvious damage was ob-
served in pCpG-huIFNc-treated chimeric mouse liver
compared with the liver of pCpG-gLuc-treated chimeric mice.
Moreover, IFN-c expression resulted in no apparent reduction
of mice serum HSA levels (Fig. 3), suggesting that sustained
IFN-c exposure would not induce severe toxicity in the liver.
FIG. 2. Effects of intrave-
nous injection of pCMV-
huIFNc in HCV 1b-infected
mice. (A–D) Mice that had
been injected with HCV-
positive human serum from
patient-A received 250 lg of
pCMV-huIFNc. Panels (A–D)
correspond to pCMV #1–4,
respectively. Serum con-
centration of HCV RNA copy
number (B), HSA (6) and
IFN-c (,) is shown. The
horizontal dashed line repre-
sents the detection limit (103
copies/ml for HCV RNA and
18 pg/ml for IFN-c). ‘‘(-)’’ on
the vertical axis indicates
negative for HCV by nested
PCR. Dagger ({) indicates the
time at which the mice died.
(E) Nested PCR in pCMV-
huIFNc-treated mouse livers
(lane 2: pCMV #1). Mouse
livers with (lane 1) or without
(lane 3) HCV infection were
also analyzed as controls.
HCV, hepatitis C virus; PCR,
polymerase chain reaction.
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FIG. 3. Effects of intravenous injection of pCpG-huIFNc in HCV 1b-infected mice. (A–F) Mice that had been injected with
HCV-positive human serum from either patient-A or patient-B received 250 lg of pCpG-huIFNc. Panels (A–F) correspond to
pCpG #1–6, respectively. Serum concentration of HCV RNA copy number (B), HSA (6) and IFN-c (,) is shown. The
horizontal dashed line represents the detection limit (103 copies/mL). ‘‘(-)’’ on the vertical axis indicates negative for HCV by
nested PCR. Dagger ({) indicates the time at which the mice died. (G) Nested PCR in pCpG-huIFNc-treated mouse livers
(lanes 2–4: pCpG #1–3). Mice livers with (lane 1) or without (lane 5) HCV infection were also analyzed as controls.
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Discussion
Human hepatocyte chimeric mice are useful model ani-
mals and have been used in variety of basic experiments
involving pharmacological and toxicological investigations
associated with drug metabolism by cytochrome P450s
(Katoh et al., 2008; Yoshizato and Tateno, 2009; Sanoh et al.,
2012) and mechanistic studies of viral infections (Sainz Jr.
et al., 2012), as well as in therapeutic approaches to HCV
infection (Hiraga et al., 2007; Meuleman et al., 2012). In the
present study, we utilized human hepatocyte chimeric mice
to test our hypothesis that a sustained IFN-c supply could be
a promising therapeutic option for the treatment of chronic
HCV infection.
The present study has demonstrated that a single gene
transfer of IFN-c can result in a significant antiviral effect on
human HCV in human hepatocyte chimeric mice with high
HCV RNA titers (105–107 copies/ml). To our knowledge, this
is the first report that clearly demonstrates the in vivo effec-
tiveness of IFN-c on a high titer HCV infection model. It was
apparent that the anti-HCV effect obtained by pCpG-huIFNc
in this study was significantly greater than that of IFN-c re-
combinant protein in the same chimeric mouse model under a
similar high HCV burden (Ohira et al., 2009). Anti-HCV effects
were observed after repeated administration of recombinant
human IFN-c at high doses (1· 105 IU on the first day and
thereafter 2· 104 IU/day for 13 days) when the serum HCV
RNA titers were < 103 copies/ml. However, when the titers
increased (> 103 copies/ml), the preventive effects of recom-
binant IFN-c on HCV infection were no longer observed. In
the present study, HCV rebound was not observed for up to 8
weeks after a single gene transfer of pCpG-huIFNc (Fig. 3),
and the sustained HCV RNA elimination from the liver was
confirmed by nested PCR. As hydrodynamic injection of
pCpG-huIFNc results in IFN-c transgene expression in the li-
ver, high local concentration of IFN-c in the liver may be a
reason for the strong antiviral effect. Further study is required
to determine whether IFN-c gene delivery into other organs
than the liver shows a significant anti-HCV effect.
In the present study, we also tested the anitviral effect of
transient IFN-c expression by using pCMV-huIFNc. Serum
concentration of IFN-c in the chimeric mice injected with
pCMV-huIFNc was lower and less sustained than that in the
mice injected with pCpG-huIFNc, although IFN-c expression
from pCMV-huIFNc was more persistent in the chimeric
mice compared with that in ICR mice (Fig. 1A). As far as
antiviral effect was concerned, only a marginal or no effect
was obtained in mice that received pCMV-huIFNc. It is
noteworthy that HCV rebound was observed in the pCMV-
huIFNc-treated mice with reduced HCV titer in serum,
suggesting that long-term IFN-c supplementation is more
favorable for preventing HCV rebound.
We have summarized the IFN-c pharmacokinetics and
anti-HCV effects after IFN-c gene transfer in Table 1. In the
case of a high virus titer ( > 4 · 106 copies/ml serum), a strong
antiviral effect was observed in a mouse that showed a high
IFN-c AUC (5.6 · 107 pg$day/ml; pCpG #1) and in a mouse
exhibiting a moderate IFN-c AUC (1.3 · 105 pg$day/ml;
pCpG #5). However, little or no antiviral effect was observed
in mice with a high virus titer ( > 4 · 106 copies/ml serum)
and a small IFN-c AUC (< 105 pg$day/ml; pCMV #2–4 and
pCpG #6). When the virus titer was relatively low (< 4· 106
copies/ml serum), viral clearance or a strong antiviral effect
was observed irrespective of the IFN-c AUC (pCMV #1,
pCpG #2–4). These results indicate that a higher IFN-c con-
centration is required to obtain anti-HCV effects in HCV
infection with a high titer, while a relatively low IFN-c
concentration is enough to obtain anti-HCV effects in HCV
infection with a low titer. In addition to the duration of IFN-c
expression, a transient high concentration of IFN-c may
contribute to a potent antiviral effect, as shown in pCMV #1.
We also found that the rate of HCV reduction after IFN-c
was different among mice; that is, the HCV titer in pCpG #3
and #4 decreased more rapidly than that in the other re-
sponding mice. Although the detailed mechanism is not
clear, there was a tendency that the higher the HCV titer, the
slower the response to IFN-c gene expression, indicating that
HCV titer is also an important factor in determining the re-
sponse of IFN-c treatment.
SCID mice without functional T and B lymphocytes pos-
sess normal NK cell function and elevated hemolytic com-
plement activity and retain their innate immune response
Table 1. Summary of Interferon-c Pharmacokinetic Parameters and Anti–Hepatitis C Virus Effects













pCMV #1 Patient-A 1.2 · 106 1.3 · 107 8.0 · 104 17 –
pCMV #2a Patient-A 1.1 · 107 2.0 · 107 7.5 · 104 14 +
pCMV #3a Patient-A 4.5 · 106 1.1 · 107 6.1 · 103 14 +
pCMV #4 Patient-A 5.0 · 106 7.4 · 106 2.0 · 103 1.8 +
pCpG #1 Patient-A 1.8 · 107 7.6 · 106 5.6 · 107 27 -
pCpG #2 Patient-A 8.8 · 105 9.0 · 106 5.1 · 105 25 -
pCpG #3 Patient-B 3.3 · 105 1.1 · 107 1.6 · 107 27 -
pCpG #4a Patient-A 2.1 · 106 4.6 · 106 6.2 · 103 4.6 -
pCpG #5a Patient-A 1.6 · 107 7.8 · 106 1.3 · 105 13 –
pCpG #6 Patient-A 1.9 · 107 1.5 · 107 1.3 · 104 13 +
pCMV #1–4 correspond to Fig. 2A–D, and pCpG #1–6 correspond to Fig. 3A–F, respectively.
aMouse died before the end of the experiments.
AUC, area under the serum concentration–time curve; HCV, hepatitis C virus; IFN, interferon.
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FIG. 4. Effects of pCpG-gLuc (control plasmid DNA) injection in HCV 1b-infected mice. Mice were injected intravenously
with HCV-positive serum from patient-A. HCV-infected chimeric mice were injected with 250lg of pCpG-gLuc. Data for
individual mice are shown in panels (A–D). Serum concentration of HCV RNA copy number (B), HSA (6) and gLuc activity
(,) is shown. The horizontal dashed line represents the detection limit (103 copies/mL). ‘‘(-)’’ on the vertical axis indicates
negative for HCV by nested PCR.
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(Shultz et al., 1995). It is possible that introduction of IFN-c
produced anti-HCV effects by activation of resident NK cells.
In the present study, flow cytometry analysis showed that
activated NK cells were present in the liver 3 days after
pCpG-huIFNc treatment (Supplementary Fig. S3). However,
the NK cell populations in the pCpG-huIFNc-treated mouse
livers were similar to those in pCpG-gLuc-treated mice.
These results indicate that the anti-HCV effect of IFN-c in
this study seems to be caused by direct inhibition of viral
replication.
During the observation period in the present study, two
out of six mice injected with pCpG-huIFNc died and two
mice died after pCMV-huIFNc injection. This was not caused
by IFN-c expression because the level of expressed IFN-c was
relatively low in the dead mice compared with that of sur-
vived mice. Vanwolleghem et al. (2010) have reported that
chimeric mice are weak, and approximately 50% of mice die
spontaneously 6 weeks after transplantation. In fact, we also
observed some chimeric mice receiving hydrodynamic in-
jection without plasmid DNA spontaneously died in pre-
liminary experiments. Therefore, these four mice were highly
unlikely to have died from hydrodynamic injection of IFN-c-
expressing plasmid DNA.
As a high level of IFN-c might produce toxicity, we
measured the serum level of ALT in the chimeric mice. On
day 3 after injection of pCpG-huIFNc, transient increase in
the serum level of ALT was observed in the mice that ex-
pressed a relatively high level of IFN-c (Fig. 5). However, 2
weeks after the gene transfer, the serum level of ALT re-
turned to the level comparable with that obtained before the
gene transfer. In the case of pCpG-gLuc injection, no signif-
icant change was observed (data not shown). Although these
results suggest that a high level of IFN-c expression in the
liver may cause slight hepatotoxicity for a short period,
which was not detected by histological analysis (Fig. 6C and
D), the effect would be transient and limited. The serum level
of HSA, an indicator of human hepatocyte number in chi-
meric mouse livers, did not markedly change after gene
transfer of IFN-c, and a sustained and constant transgene
expression from pCpG vectors from the hepatocytes in the
chimeric mice was also observed, implying that transgene-
expressing hepatocytes were not damaged by IFN-c. Histo-
chemical analysis by hematoxylin–eosin staining of the liver
sections also suggested that there was no significant damage
in human hepatocytes even after long-term exposure to the
human cytokine, IFN-c (Fig. 6G and H). Taken together,
these results suggest that sustained IFN-c treatment would
be tolerable in terms of hepatic toxicity induced by IFN-c.
In the development of IFN-c gene therapy as the treatment
of patients with chronic HCV infection, the method of gene
delivery presents a major challenge. In the present study, we
found that human hepatocytes in the mouse liver can be
transfected by hydrodynamic injection with a large variation
in the transfection efficiency among the mice tested. Al-
though the reasons for this variable transfection efficiency in
human liver chimeric mice are not clear, some speculations
FIG. 5. Serum ALT levels in chimeric mice receiving hydrodynamic injections. Serum ALT levels in chimeric mice receiving
pCpG-huIFNc were measured. Panels (A–F) correspond to pCpG #1–6, respectively. N.D. indicates that serum ALT activity
was not determined because of the exhaustion of serum sample. ALT, alanine aminotransferase.
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are possible. As poorly vascularized regions were observed
on occasion in the liver of the chimeric mice, this might be
the reason for the poor transfection efficiency and variability
in transfection efficiency between mice (Sato et al., 2008).
Although the difference in the repopulation rate of human
hepatocytes may affect the transgene gene expression level,
an apparent correlation between transgene expression level
and repopulation rate was not observed. In addition, there
was no apparent effect of HCV level in the liver on IFN-c
transgene expression level. A recent study demonstrated that
significant transgene expression is obtained in human liver
segments after hydrodynamic injection; however, a very fast
injection speed was required compared with that for mice
(Herrero et al., 2012). In addition, special attention should be
paid when hydrodynamic gene transfer is performed in cir-
rhotic livers, because the transgene expression level obtained
by this method has been shown to be lower in cirrhotic liver
in rats (Yeikilis et al., 2006). Under these circumstances, gene
transfer to organs other than the liver, such as skeletal
muscle, could be an option.
FIG. 6. Histological analysis of the
liver of the pCpG-huIFNc-treated chi-
meric mice. The livers of HCV-infected
chimeric mice that had been untreated
(A and B) or that had been injected
with plasmid vectors were collected at
3 days after pCpG-huIFNc adminis-
tration (C and D). In a separate set of
experiments, the livers of HCV-in-
fected chimeric mice were collected at
56 days after the administration of
pCpG-gLuc (E and F) or pCpG-huIFNc
(pCpG #3; G and H). The liver sections
were histologically examined either
by hematoxylin–eosin staining (A, C,
E, and G) or immunohistochemical
staining with antihuman serum albu-
min antibody (B, D, F, and H). Origi-
nal magnification, · 100. Color images
available online at www.liebertpub
.com/humc
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In conclusion, the present study has demonstrated that
long-term elimination of human HCV in human hepatocyte
chimeric mice with high titers of HCV RNA of genotype 1b
can be achieved by IFN-c exposure after systemic adminis-
tration of pCpG-huIFNc. These results indicate that continu-
ous supply of IFN-c, such as through IFN-c gene transfer,
appears to be a promising antiviral treatment for chronic HCV.
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